Cana, as a highly potent and selective SGLT2 inhibitor, has shown to lower the renal threshold for glucose, increase urinary glucose excretion, improve glycemic control and beta-cell function in rodent models of type 2 diabetes mellitus, and to reduce body-weight gain in rodent models of obesity [13]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.